Adult Chronic Kidney Disease Monitoring and Treatment Targets
KDIGO adult CKD management is addressed by the KDIGO 2024 Clinical Practice Guideline for evaluation and management of CKD, with blood-pressure targets provided by the KDIGO 2021 Clinical Practice Guideline for management of blood pressure in CKD. [1] A specific KDIGO 2026 “CKD evaluation and management” guideline update for general adult CKD management was not identified in the retrieved KDIGO CKD guideline sources; the KDIGO 2026 publication identified relates to diabetes management in CKD. [2]
Monitoring Frequency for CKD Progression and Therapy Safety
Albuminuria and GFR should be assessed at least annually in adults with CKD. [1] More frequent monitoring is recommended for individuals at higher risk of CKD progression or when measurement will impact therapeutic decisions. [1] A stage-based monitoring frequency approach is described as follows: [1]
- CKD G1–G2: assessment about annually. [1]
- CKD G3: assessment about every 6 months. [1]
- CKD G4: assessment about every 3 months. [1]
- CKD G5: assessment about every 6 weeks. [1] GFR and albuminuria should be rechecked after initiation of hemodynamically active therapies when clinically indicated, because expected early eGFR decline is hemodynamically mediated rather than automatically requiring therapy discontinuation. [1] GFR reduction patterns that exceed expected biological/analytical variability should prompt evaluation (examples include >20% eGFR change for general monitoring evaluation, and >30% eGFR reduction after initiation of hemodynamically active therapies). [1]
Blood Pressure Targets in Adults With CKD
KDIGO recommends a target systolic blood pressure (SBP) of <120 mm Hg when tolerated for adults with high BP and CKD, using standardized office BP measurement. (Class/level as stated in KDIGO 2021 guideline: 2B). [3] Less intensive BP lowering should be considered for frailty, high fall/fracture risk, very limited life expectancy, or symptomatic postural hypotension. [1]
Pharmacologic Therapy for Delaying CKD Progression
Comprehensive CKD risk modification is recommended as a multi-component strategy to reduce risks of progression and associated complications. [1]
Renin-Angiotensin System Inhibitors
RAS blockade with an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is recommended for adults with CKD and moderately-to-severely increased albuminuria (G1–G4, A2 and A3) with diabetes. (Recommendation 3.6.3; 1B). [1] RAS combination therapy should be avoided; any combination of ACEi, ARB, and direct renin inhibitor therapy is recommended to be avoided. (Recommendation 3.6.4; 1B). [1] ACEi/ARB therapy should be continued unless serum creatinine rises by more than 30% within 4 weeks after initiation or dose increase. [1]
SGLT2 Inhibitors
SGLT2 inhibitor therapy is recommended as kidney-protective treatment in appropriate CKD populations with albuminuria and/or risk features described in the guideline sections addressing SGLT2i use. [1] KDIGO specifically suggests SGLT2 inhibitor treatment for adults with eGFR 20 to 45 ml/min per 1.73 m2 with urine ACR <200 mg/g (<20 mg/mmol). (Recommendation 3.7.3; 2B). [1] SGLT2 inhibitor initiation or use does not necessitate alteration of CKD monitoring frequency in the guideline’s practice point addressing CKD surveillance. [1]
Mineralocorticoid Receptor Antagonists and Potassium Monitoring
For adults with type 2 diabetes and CKD, a nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) with proven kidney or cardiovascular benefit is suggested when criteria are met, including eGFR >25 ml/min per 1.73 m2 and normal serum potassium, with albuminuria >30 mg/g (>3 mg/mmol) despite other therapy. (Recommendation 3.8.1; KDIGO 2022 diabetes-in-CKD guideline recommendation highlighted in KDIGO 2024 CKD guideline). [1] Serum potassium monitoring during ns-MRA therapy is operationalized in the guideline with a figure and practice details that include monitoring K+ at 4-month intervals in the described protocol. [1]
Glucose-Lowering Pharmacotherapy for CKD in Diabetes
In adults with T2D and CKD who have not achieved individualized glycemic targets despite metformin and SGLT2 inhibitor treatment, or who cannot use those medications, KDIGO recommends a long-acting GLP-1 receptor agonist (GLP-1 RA). (Recommendation 3.9.1; 1B). [1]
Statin Therapy for Atherosclerotic Cardiovascular Risk
In CKD, statin-based regimens should be chosen to maximize the absolute reduction in LDL cholesterol to achieve the largest treatment benefits. [1]